<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39316327</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8229</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Infectious diseases and therapy</Title><ISOAbbreviation>Infect Dis Ther</ISOAbbreviation></Journal><ArticleTitle>Letter to the Editor: "Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19".</ArticleTitle><Pagination><StartPage>2461</StartPage><EndPage>2462</EndPage><MedlinePgn>2461-2462</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40121-024-01053-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hagiya</LastName><ForeName>Hideharu</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5086-1891</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan. hagiya@okayama-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Dis Ther</MedlineTA><NlmUniqueID>101634499</NlmUniqueID><ISSNLinking>2193-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Ensitrelvir</Keyword><Keyword MajorTopicYN="N">Hospitalization</Keyword></KeywordList><CoiStatement>Hideharu Hagiya has nothing to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>11</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39316327</ArticleId><ArticleId IdType="pmc">PMC11499574</ArticleId><ArticleId IdType="doi">10.1007/s40121-024-01053-7</ArticleId><ArticleId IdType="pii">10.1007/s40121-024-01053-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Takazono T, Fujita S, Komeda T, Miyazawa S, Yoshida Y, Kitanishi Y, et al. Real-world effectiveness of ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19. Infect Dis Ther. 2024. 10.1007/s40121-024-01010-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11266320</ArticleId><ArticleId IdType="pubmed">38941067</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato S, Yasunaga H. A review of studies using Japanese nationwide administrative claims databases. Ann Clin Epidemiol. 2023;5:58–64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10944998</ArticleId><ArticleId IdType="pubmed">38505730</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerowitz EA, Scott J, Richterman A, Male V, Cevik M. Clinical course and management of COVID-19 in the era of widespread population immunity. Nat Rev Microbiol. 2024;22:75–88.</Citation><ArticleIdList><ArticleId IdType="pubmed">38114838</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>